Mylan Inc.

NASDAQ: MYL
$15.86
+$0.00 (+0.0%)
Closing Price on November 19, 2020

MYL Articles

Mylan is scheduled to release its first-quarter financial results before the markets open on Tuesday, and earnings are expected to be lower than a year ago.
24/7 Wall St. has put together a preview of the most prominent earnings reports expected this week, including Disney, Lyft and Electronic Arts.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Allergan, Costco, Cree, Dollar Tree, Eli Lilly, FedEx, Mylan, NextEra Energy, Peabody Energy, Teva Pharmaceutical and...
The top analyst upgrades, downgrades and initiations seen on Wednesday included CSX, Intelsat, Kohl's, NIO, Rio Tinto, Teva Pharmaceutical, TripAdvisor and VMware.
Wednesday was a flat day for the broad U.S. markets. We saw Best Buy’s report lead retailers today. And as this week goes on we are looking forward to some more major retailers posting their...
The top analyst upgrades, downgrades and initiations seen on Wednesday included Benefitfocus, Chubb, Dominion Energy, Home Depot, Karyopharm Therapeutics, Mylan, Philip Morris and Weight Watchers.
More and more branded drugs seem to be facing generic competition. The impact might not be so positive for Big Pharma giants, but this can be a serious victory for consumers and patients who are in...
The top analyst upgrades, downgrades and initiations seen on Wednesday included Alphabet, Amazon.com, Dell Technologies, IBM, International Paper, Merck, Pfizer, Tesla, Teva Pharmaceutical and...
The top analyst upgrades, downgrades and other research calls from Wednesday included Altice, Blue Apron, CubeSmart, Horizon Pharma, KB Home, Las Vegas Sands, Mylan and Switch.
Here 24/7 Wall St. has included 10 stocks that saw the best earnings performance so far this season.
The top analyst upgrades, downgrades and initiations seen on Tuesday included AbbVie, AMAG Pharmaceuticals, Crocs, HCA, Kellogg, Kosmos Energy, Mylan, Pandora Media and Square.
Mylan reported better-than-expected quarterly results late Monday, and shares rose sharply in Friday's premarket.
Mylan shares hit a 52-week low after Mapi Pharma announced midstage results from its multiple sclerosis trial.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Apple, Baker Hughes, Blackbaud, Box, CSX, Intuit, Mylan, Tesla, Vodafone and Walmart.
The top analyst upgrades, downgrades and initiations seen on Friday included Carbonite, Cleveland-Cliffs, Conoco, Costco, EA, Eli Lilly, HP, PepsiCo and Roku.